

Kathryn Lurain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5169471/publications.pdf>

Version: 2024-02-01

19
papers

708
citations

759233

12
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

1005
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. <i>Journal of Clinical Oncology</i> , 2022, 40, 294-306. | 1.6 | 17 |
| 2 | Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836. | 12.4 | 50 |
| 3 | A Mixed Blood-Lymphatic Endothelial Cell Phenotype in Lymphangioliomyomatosis and Idiopathic Pulmonary Fibrosis but Not in Kaposi's Sarcoma or Tuberous Sclerosis Complex. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 337-340. | 2.9 | 3 |
| 4 | Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. <i>Clinical Cancer Research</i> , 2022, 28, 840-850. | 7.0 | 20 |
| 5 | Immunotherapy for KSHV-associated diseases. <i>Current Opinion in Virology</i> , 2022, 55, 101249. | 5.4 | 4 |
| 6 | Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097. | | 28 |
| 7 | Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670. | 5.2 | 35 |
| 8 | Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. <i>Aids</i> , 2021, 35, 53-62. | 2.2 | 6 |
| 9 | Dual infection and recombination of Kaposi sarcoma herpesvirus revealed by whole-genome sequence analysis of effusion samples. <i>Virus Evolution</i> , 2020, 6, veaa047. | 4.9 | 5 |
| 10 | Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556. | 3.1 | 21 |
| 11 | Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <i>Blood</i> , 2020, 135, 2316-2319. | 1.4 | 33 |
| 12 | Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. <i>Blood</i> , 2020, 136, 2229-2232. | 1.4 | 26 |
| 13 | Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2027110. | 5.9 | 15 |
| 14 | Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332. | 7.1 | 153 |
| 15 | A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4238-4247. | 7.0 | 17 |
| 16 | Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761. | 1.4 | 87 |
| 17 | Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 75-88. | 2.2 | 36 |
| 18 | Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12805-12810. | 7.1 | 144 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Emergence of Kaposi's Sarcoma Herpesvirus-Associated Complications Following Corticosteroid Use in TB-IRIS. Open Forum Infectious Diseases, 2018, 5, ofy217. | 0.9 | 8 |